跳至主要内容

博文

目前显示的是标签为“NSCLC”的博文

正大天晴国内开启两项TQB2450联合安罗替尼用于非小细胞肺癌临床Ib期研究

今日正大天晴公示最新临床研究 PD-L1抑制剂联合VEGFR抑制剂 (即TQB2450联合安罗替尼) 用于治疗NSCLC的Ib期临床研究 NCT03910127 另外 同时开启的还有二者联合 用于晚期突变阳性的非小细胞肺癌 临床Ib期研究 NCT03910270 目前TQB2450已开启多个临床研究 包括NSCLC/TNBC/NSCLC/HCC等适应症 如下所示 NCT03910127 Study Design Go to   Study Type   : Interventional  (Clinical Trial) Estimated  Enrollment   : 90 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Phase Ib, Multicenter, Randomized Study to Evaluate the Pharmacokinetics, Efficacy and Safety of TQB2450 Combined With or Without Anlotinib in Patients With Advanced Non-small Cell Lung  Cancer (NSCLC) Estimated  Study Start Date   : April 1, 2019 Estimated  Primary Completion Date   : December 31, 2020 Estimated  Study Completion Date   : June 30, 2021 Arms and Interventions    Arm  Intervention/treatment  Experimental: TQB2450 +